reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. many of these diseases are associated with deficits in cellular metabolism and energy production. our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting. we are currently advancing a novel molecule into several diseases. our experienced team of drug development experts, who have collaborated in many successful programs, are dedicated and passionate about finding effective therapies for these complex rare diseases.
Company profile
Ticker
RPHM
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Reneo Pharma Ltd ...
IRS number
472309515
RPHM stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
28 Mar 24
8-K
Cost Associated with Exit or Disposal Activities
23 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
14 Dec 23
EFFECT
Notice of effectiveness
22 Nov 23
CORRESP
Correspondence with SEC
17 Nov 23
UPLOAD
Letter from SEC
16 Nov 23
S-3
Shelf registration
13 Nov 23
Latest ownership filings
SC 13G
Octagon Capital Advisors LP
5 Feb 24
SC 13G
BML Investment Partners, L.P.
17 Jan 24
SC 13D
TANG CAPITAL PARTNERS LP
26 Dec 23
SC 13D/A
Novo Holdings A/S
15 Dec 23
4
Ashley Hall
29 Aug 23
144
Notice of proposed sale of securities
28 Aug 23
4
MICHAEL G GREY
27 Jul 23
4
Change in insider ownership
23 Jun 23
144
Notice of proposed sale of securities
23 Jun 23
4
Edward T Mathers
8 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.74 mm | 11.74 mm | 11.74 mm | 11.74 mm | 11.74 mm | 11.74 mm |
Cash burn (monthly) | (no burn) | 4.20 mm | 6.96 mm | 6.05 mm | 6.26 mm | 4.96 mm |
Cash used (since last report) | n/a | 28.94 mm | 47.98 mm | 41.70 mm | 43.11 mm | 34.19 mm |
Cash remaining | n/a | -17.20 mm | -36.24 mm | -29.96 mm | -31.37 mm | -22.45 mm |
Runway (months of cash) | n/a | -4.1 | -5.2 | -5.0 | -5.0 | -4.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 60 |
Opened positions | 10 |
Closed positions | 4 |
Increased positions | 21 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 203.55 bn |
Total shares | 36.24 mm |
Total puts | 200.00 |
Total calls | 700.00 |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
NEA Management | 4.79 mm | $36.44 bn |
New Enterprise Associates 15 | 4.79 mm | $58.53 mm |
Novo Holdings A/S | 3.33 mm | $25.34 bn |
CG Carlyle Group Inc | 2.70 mm | $20.54 bn |
RiverVest Venture Management | 2.53 mm | $19.30 bn |
Octagon Capital Advisors | 2.28 mm | $17.36 bn |
RiverVest Venture Fund III | 2.19 mm | $20.49 mm |
Eventide Asset Managment | 2.08 mm | $15.83 bn |
Lundbeckfond Invest A/S | 2.03 mm | $17.37 mm |
BEN Franklin Resources | 1.49 mm | $11.37 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Aug 23 | Ashley Hall | Common Stock | Sell | Dispose S | No | No | 6.2757 | 15,625 | 98.06 k | 39,600 |
28 Aug 23 | Ashley Hall | Common Stock | Option exercise | Acquire M | No | No | 1.8 | 15,625 | 28.13 k | 55,225 |
28 Aug 23 | Ashley Hall | Stock option Common Stock | Option exercise | Dispose M | No | No | 1.8 | 15,625 | 28.13 k | 109,375 |
26 Jul 23 | Grey Michael G | Common Stock | Gift | Dispose G | No | No | 0 | 50,000 | 0.00 | 0 |
23 Jun 23 | Novo Holdings A/S | Common Stock | Sell | Dispose S | No | No | 7.0974 | 100,000 | 709.74 k | 3,330,337 |
6 Jun 23 | Eric M Dube | Stock Option Common Stock | Grant | Acquire A | No | No | 9.01 | 17,500 | 157.68 k | 17,500 |
6 Jun 23 | Seltzer Stacey Denenberg | Stock Option Common Stock | Grant | Acquire A | No | No | 9.01 | 17,500 | 157.68 k | 17,500 |